Immune rejection of intracerebral gliomas using lymphocytes from glioma-bearing rats

Journal of Immunotherapy

Volumn 22, Issue 6, 1999, Pages 497-505

  Wood, Gary W ^a   Turner, Teresa ^a   Wang, Yu Ying ^a   Holladay, Frank P ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Adoptive transfer; Astrocytoma; Brain cancer; Cell mediated immunity; Cytotoxic T lymphocyte

Indexed keywords

TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLONAL ANERGY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GLIOMA; LYMPHOCYTE TRANSFER; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION;

ANIMALS; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; GLIOMA; IMMUNIZATION; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; RATS; RATS, INBRED F344; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0032726152     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199911000-00004     Document Type: Article

References (20)

1. Klein G. Cancer-specific transplantation antigens. Cancer Res 1968;28:625-35.
2. North RJ. The murine anti-cancer immune response and its therapeutic manipulation. Adv Immunol 1984;35:89-122.
3. van der Bruggen P, van den Eynde B. Molecular definition of cancer antigens recognized by T lymphocytes. Curr Opin Immunol 1992;4:608-12.
4. Cheever MA, Greenberg PD, Gillis S, Fefer A. Specific adoptive therapy of murine leukemia with cells secondarily sensitized in vitro and expanded in IL-2. Progr Cancer Res Ther 1982;22:127-33.
5. Chang AE, Shu S. Immunotherapy with sensitized lymphocytes. Cancer Invest 1992;10:357-69.
6. Yamasaki T, Handa H, Yamashita J, Watanabe Y, Namba Y, Hanaoka M. Specific adoptive immunotherapy with a tumor-specific cytotoxic T lymphocyte clone for murine malignant gliomas. Cancer Res 1984;44:1776-83.
7. Holladay FP, Lopez G, De M, Morantz RA, Wood GW. Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells. Neurosurgery 1992;30:499-505.
8. Holladay FP, Heitz T, Chen Y-L, Wood GW. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes. Neurosurgery 1992;31:528-33.
9. Holladay FP, Heitz T, Wood GW. Cytotoxic T lymphocytes, but not lymphokine activated killer cells, exhibit anti-tumor activity against established intracerebral gliomas. J Neurosurg 1992;77: 757-62.
10. Plautz GE, Toualisky JE, Shu S. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor draining lymph node cells. Cell Immunol 1997;178:101-7.
11. Baldwin NG, Rice CD, Bear HD. Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. Neurol Res 1997;19:145-52.
12. Mahaley MS, Brooks WH, Rozman TL, Bigner DD, Dudka L, Richardson S. Immunobiology of primary intracranial tumors. Part 1: Studies of the cellular and humoral general immune competence of brain-tumor patients. J Neurosurg 1977;46:467-76.
13. Wood GW, Morantz RA. Depressed T lymphocyte function in brain tumor patients: monocytes as suppressor cells. J Neurooncol 1983;1:87-94.
14. Tawfik OW, Hunt JS, Wood GW. Soluble suppressor factors produced by decidual cells during pregnancy are prostaglandins. Am J Reprod Immunol 1986;12:111-7.
15. Correa MR, Ochoa AC, Ghosh P, Mizoguchi H, Harvey L, Longo DL. Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J Immunol 1997;158: 5292-6.
16. Charlton B, Auchincloss H, Fathman CG. Mechanisms of transplantation tolerance. Annu Rev Immunol 1994;12:707-34.
17. Nossal GJ. Negative selection of lymphocytes. Cell 1994;76:229-39.
18. Miller JF, Morahan G. Peripheral T cell tolerance. Annu Rev Immunol 1992;10:51-69.
19. Jarpe MA, Hayes MP, Russell JK, Johnson HM, Russell SW. Causal association of IFN-7 with tumor regression. J Leuk Biol 1989;9:2139-44.
20. + tumor-infiltrating lymphocytes. J Exp Med 1991; 173:647-58.